EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieMultizentrische Studie

Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis

Jiwon Oh iD, Douglas L Arnold, Bruce A C Cree, Carolina Ionete, Ho Jin Kim, Maria Pia Sormani iD, Sana Syed, Yixin Chen, Christina R Maxwell, Patrick Benoit, Timothy J Turner, Erik Wallstroem und 2 weitere

New England Journal of Medicine · 2025

DOI: 10.1056/nejmoa2415985 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2025. Verfasst von Jiwon Oh und 13 weiteren Autor:innen. Beteiligte Einrichtung: St. Michael's Hospital, University of Toronto, Toronto. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Multiple Sclerosis, Relapsing-Remitting, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseMultiple Sclerosis, Relapsing-RemittingTyrosine Kinase InhibitorsAdultFemaleHumansMaleMiddle AgedDisability EvaluationDouble-Blind MethodHemorrhageTreatment OutcomeRecurrenceCrotonatesHydroxybutyratesNitrilesToluidines

Substanzen

Agammaglobulinaemia Tyrosine KinaseBTK protein, humanteriflunomideTyrosine Kinase InhibitorsCrotonatesHydroxybutyratesNitrilesToluidines

Autor:innen und Institutionen

  • St. Michael's Hospital, University of Toronto, Toronto.
  • McGill University, Montreal.
  • NeuroRx Research, Montreal.
  • Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco.
  • Department of Neurology, UMass Chan Medical School, Worcester, MA.
  • Department of Neurology, National Cancer Center, Goyang, South Korea.

ORCID-Profile: Jiwon Oh, Maria Pia Sormani

Förderung

  • Sanofi

Zitieren

APA

Oh, J., Arnold, D. L., Cree, B. A. C., Ionete, C., Kim, H. J., Sormani, M. P., Syed, S., Chen, Y., Maxwell, C. R., Benoit, P., Turner, T. J., Wallstroem, E., Wiendl, H., & Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group (2025). Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2415985

Vancouver

Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, et al. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine. 2025. doi:10.1056/nejmoa2415985

BibTeX
@article{Oh2025,
  author = {Oh, Jiwon and Arnold, Douglas L and Cree, Bruce A C and Ionete, Carolina and Kim, Ho Jin and Sormani, Maria Pia and Syed, Sana and Chen, Yixin and Maxwell, Christina R and Benoit, Patrick and Turner, Timothy J and Wallstroem, Erik and Wiendl, Heinz and Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group, Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group},
  title = {Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis},
  journal = {New England Journal of Medicine},
  year = {2025},
  doi = {10.1056/nejmoa2415985}
}
Kostenlos starten →